* **4. Confirmations from the Applicant**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **4.1 The Applicant confirms to UK Biobank that all work performed by it using the Materials shall be carried out in compliance with:**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文：1.c. Researcher shall perform the Research and use the Data in strict compliance with: (i) this Agreement; (ii) all applicable laws, rules and regulations (including but not limited to the Health Insurance Portability and Accountability Act of 1996 and all regulations implements thereunder, ("HIPAA"); (iii) all Registry policies, procedures, and governance documents made available to Researcher; (iv) all regulatory approval documents (including but not limited to approvals of Institutional Review Boards ("IRBs"), patient informed consent forms, and patient HIPAA authorization forms; and (v) any documentation submitted by Researcher to Registry in order to gain access to the Data (e.g., Data access request forms, Research proposals).
    * 比較結果：一致
    * 判断理由：UKBBとNIHは、データを使用する研究が、適用されるすべての法律、規制、ガイドライン、および承認に厳密に従って行われるべきであるという点で一致しています。
* **4.2 The Applicant shall retain the Materials in a secure network system, at a standard which would be reasonably expected for the storage of valuable and proprietary sensitive/confidential data. In addition, the Applicant shall be obliged to implement the appropriate technical and organisational measures as set out in Annex 2 (Security Measures) to protect the Materials from the accidental or unlawful destruction, loss, alteration, unauthorised disclosure of, or access to the Materials (a "Data Security Incident"). By signing this MTA, the Applicant Pl confirms that the Security Measures set out in Annex 2 are in place in order to protect the Materials.**
    * 対応するEGAの条文：Appendix I DATASET DETAILS - Minimum protection measures required
    * 比較結果：一致
    * 判断理由：UKBBとEGAは、機密データを保護するためのセキュリティ対策（安全なネットワークシステム、パスワード保護、暗号化など）を講じることを規定しています。
    * 対応するNIHの条文：3.b. [Depending on the nature of the Data, it may be advisable to add detailed security requirements for Researcher to follow, e.g., use of encryption, password security requirements, separation of Data from other datasets, linking Data with other datasets. Security requirements also may be set forth in a Registry policy cross-referenced here].
    * 比較結果：一致
    * 判断理由：UKBBとNIHは、データのセキュリティを確保するために、暗号化やパスワードなどの詳細なセキュリティ要件を定めることを推奨または義務付けています。
* **4.3 The Applicant shall notify UK Biobank without undue delay (and in any event no later than 24 hours) after becoming aware of a reasonably suspected "near miss" or actual Data Security Incident which affects the Materials. Such notification must be sent by email to DPO@ukbiobank.ac.uk with a copy to access@ukbiobank.ac.uk.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文：1.e. Researcher shall use appropriate safeguards to prevent use or disclosure of the Data other than as provided by this Agreement. Researcher shall notify Registry within [may consider inserting a specific timeframe, e.g., two (2) business days, or a more general requirement, e.g., immediately/promptly upon discovery] of any uses or disclosures of Data not permitted by this Agreement.
    * 比較結果：部分一致
    * 判断理由：UKBBはデータセキュリティインシデントについて具体的な通知期限を設けていますが、NIHは許可されていない使用や開示の通知について言及しており、内容が部分的に一致しています。
* **4.3.1 The Applicant shall not delay such notification on the basis that the information is incomplete, or the relevant investigation is ongoing. Further, the Applicant shall not make any external announcement, notifications to a supervisory authority or regulator about any such Data Security Incident without the express prior written consent of UK Biobank, unless required by law to do so.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **4.3.2 Both parties shall cooperate and provide reasonable assistance to each other to facilitate the handling of the Data Security Incident.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **4.4 The Applicant confirms that it shall deal promptly and appropriately (in accordance with the Participants option to withdraw as set out on the UK Biobank website here) with any "no further use" withdrawals by Participants which UK Biobank notifies to the Applicant.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **4.5 The Applicant is expressly prohibited from (or attempting to):**
    * 対応するEGAの条文：4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction.
    * 比較結果：一致
    * 判断理由：UKBBとEGAは、研究参加者を再特定するためにデータをリンクまたは再構築することを明確に禁止しています。
    * 対応するNIHの条文はありません
* **4.5.1 developing, linking or re-engineering the Materials supplied to it so as to identify (directly or indirectly) any Participant;**
    * 対応するEGAの条文：4. The User Institution agrees not to link or combine these Data to other information or archived data available in a way that could re-identify the Research Participants, even if access to that data has been formally granted to the User Institution or is freely available without restriction.
    * 比較結果：一致
    * 判断理由：UKBBとEGAは、データの結合や再特定を明確に禁止しています。
    * 対応するNIHの条文はありません
* **4.5.2 identifying any Participant from the Materials provided by UK Biobank; or**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **4.5.3 contacting any Participant.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **4.6 In the event that the Applicant inadvertently identifies any Participant then it shall notify UK Biobank immediately setting out (in reasonable detail) the circumstances by which it happened. Such notification must be sent by email to DPO@ukbiobank.ac.uk with a copy to access@ukbiobank.ac.uk.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **4.7 Other than for the purposes of clause 4.6, the Applicant shall not:**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **4.7.1 share the identification of that Participant with any other person; or**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **4.7.2 attempt to contact the Participant themselves.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **4.8 Without prejudice to the other provisions of this MTA, any actual or anticipatory breach of any provision of clauses 4.1, 4.2 and 4.4 to 4.7 inclusive shall entitle UK Biobank to terminate this Agreement with immediate effect and require the immediate return or destruction of any Materials provided by UK Biobank.**
    * 対応するEGAの条文：15. XXXXX may terminate this agreement by written notice to the User Institution. If this agreement terminates for any reason, the User Institution will be required to destroy any Data held, including copies and backup copies.
    * 比較結果：部分一致
    * 判断理由：UKBBは特定の条文違反の場合に即時終了とデータ破棄を定めていますが、EGAは理由を問わず書面通知による終了とデータ破棄を定めており、違反時に限定していません。
    * 対応するNIHの条文：8.b. Termination: In addition, either party may terminate this Agreement upon written notice to the other party in the event of a material breach of this Agreement by the other party, which material breach is not cured within [insert number] days after receipt of written notice thereof.
    * 比較結果：部分一致
    * 判断理由：UKBBは即時終了権を定めていますが、NIHは重大な違反があった場合に通知後一定期間が経過しても是正されない場合に終了できるとしており、即時終了ではありません。
* **5. Publication of lay summary, submission of annual report and return and publication of Findings**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.1 After the Applicant has received the Materials for the Approved Research Project, UK Biobank shall be entitled to publish on its website:**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.1.1 the lay summary of the Approved Research Project contained in the Application (with the exception of any material that has been agreed by UK Biobank would be kept confidential); and**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.1.2 summary details of the Applicant.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.2 During the Term, the Applicant shall provide UK Biobank with:**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.2.1 a report (with a summary section) setting out in reasonable detail the progress of the Approved Research Project in the form attached as Annex 3 (or in such other format as required by UK Biobank from time to time) on an annual basis (from the Effective Date) which shall include the Findings the Applicant has made which in its reasonable view may be:**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.2.1 (a) published or pending publication;**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文：9. Publications [Registry may insert its desired publication requirements or otherwise attach or cross-reference its policy governing publications].
    * 比較結果：部分一致
    * 判断理由：UKBBは出版された、または出版予定の発見について年次報告書で報告することを求めていますが、NIHは出版に関する要件を追加する可能性に言及しているだけで、具体的な内容はありません。
* **5.2.1 (b) disclosed in a published patent; or**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.2.1 (c) otherwise of significance (in the context of medical research); and**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.2.2 a summary (and a copy of the application if requested) of any patents whose claims cover, or are intended to cover, an Applicant-Generated Invention within two (2) months of their publication.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.3 In relation to the Annual Project Report, UK Biobank:**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.3.1 shall have the ability to make the summary section of the Annual Project Report public, subject to the Applicant (as referred to in clause 5.7 below) retaining a reasonable period of confidentiality on items where patent rights still need to be filed; and**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.3.2 shall have the opportunity to ask the Applicant any reasonable questions arising from the Annual Project Report and the Applicant shall respond to such questions in a timely manner.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.4 If the Annual Project Report, or any other information or data provided to UK Biobank, contains any technology or data that is subject to applicable export controls, it shall be the responsibility of the Applicant to obtain any export licence that may be required to authorise the transmission of the Annual Project Report, information or data to UK Biobank. The Applicant shall notify UK Biobank at least one week in advance that an Annual Project Report, information or data is to be sent under an export licence and shall provide UK Biobank with full details of the conditions of the licence and of the reasons for the control of the technology contained in the Annual Project Report, information or data.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.5 In the event that the Annual Project Report is not received by UK Biobank in the timeframe, manner and form prescribed, then the Applicant's rights under this MTA shall be suspended and the Applicant (together with any Collaborators) will not be able to download further data (either in terms of new data fields or updates of existing data fields) or access existing data via the research access platform until such time as the Annual Project Report has been duly and compliantly provided. If the Annual Project Report is still outstanding, notwithstanding reminders from UK Biobank, 3 months after the relevant anniversary of the Effective Date, then UK Biobank has the right to terminate this MTA by giving the Applicant written notice of termination and/or prevent the Applicant Institution (or Applicant PI) from applying for or accessing any further Materials from UK Biobank.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.6 The Applicant shall use All Reasonable Endeavours to publish the Findings (and provide UK Biobank with a link thereto) within six (6) months after the Completion Date for the Approved Research Project:**
    * 対応するEGAの条文：Appendix III PUBLICATION POLICY
    * 比較結果：部分一致
    * 判断理由：UKBBは出版を奨励し、EGAは出版に関するモラトリアム期間に言及しており、両者とも出版に関する規定を持っています。
    * 対応するNIHの条文：9. Publications [Registry may insert its desired publication requirements or otherwise attach or cross-reference its policy governing publications].
    * 比較結果：部分一致
    * 判断理由：UKBBは具体的な出版期間を定めていますが、NIHは出版要件を追加する可能性に言及するのみです。
* **5.6.1 in an academic journal; or**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.6.2 on an open-source publication site.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.7 UK Biobank acknowledge and agree that the Applicant may keep such Findings confidential for a reasonable time in accordance with its reasonable research and development practices. For the avoidance of doubt, the Applicant is entitled to retain confidentiality regarding any Finding over which patent protection is being sought (and the patent has not yet been published).**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.8 If such Findings are made publicly available, UK Biobank requires that the Results Data underlying such Findings shall be promptly returned or otherwise made available to UK Biobank. UK Biobank also requires that the Results Data are returned in a format which is appropriate and comprehensible (particularly for other researchers) along with any documentation which would be reasonably necessary to enable another researcher to interpret and understand the Results Data.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.9 Within six (6) months after the publication of the Findings, the relevant Applicant shall provide to UK Biobank the Results Data in such form and format as set out in clause 5.8 above (alternatively UK Biobank and the relevant Applicant may agree that the relevant Applicant retains the Results Data on the basis that they are made publicly available to other Researchers and/or publicly available generally).**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.10 UK Biobank shall consider reasonably any written requests (containing an appropriate explanation) for an extension of the time limits set out in this clause.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.11 The Applicant shall use All Reasonable Endeavours to publish a commensurate level of Findings in relation to the Approved Research Project within the first three (3) years of the Term (and in any subsequent extensions). Where this is not possible, the Applicant shall provide UK Biobank with a reasonable explanation as to why it is not possible and an estimation of when a publication can be expected.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.12 Unless otherwise stated in Annex 4, the Applicant is not required to obtain UK Biobank's approval to any report of its Findings. The Applicant shall nevertheless provide a copy of any report of its Findings and any press release to UK Biobank at least two (2) weeks before their expected date of first public presentation or publication in any format (e.g., paper journal, on-line report, meeting abstract). The Applicant shall upload such documents to AMS in the first instance. If this is not possible, the Applicant shall email such documents to access@ukbiobank.ac.uk.**
    * 対応するEGAの条文：Appendix III PUBLICATION POLICY
    * 比較結果：部分一致
    * 判断理由：UKBBは出版前の事前通知を義務付けていますが、EGAは出版における謝辞の形式について合意することを定めています。両者とも出版前の手続きを規定しています。
    * 対応するNIHの条文：9. Publications [Registry may insert its desired publication requirements or otherwise attach or cross-reference its policy governing publications].
    * 比較結果：部分一致
    * 判断理由：UKBBは報告書の提出を求めていますが、NIHは出版に関する要件を追加する可能性に言及するのみです。
* **5.13 However, and notwithstanding the provisions of clause 5.12 above, the Applicant is required to promptly notify UK Biobank in advance (in writing) if any report of its Findings is reasonably likely to provoke controversy or otherwise attract significant public attention. In such circumstances, UK Biobank reserves the right to make such recommendations, reservations or suggestions on the report as it sees fit (and which it may make public) for consideration by the Applicant.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **5.14 UK Biobank requires that the term "UK Biobank" is incorporated within the title and/or the abstract of any and all publications.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文：9.b. [Registry may consider adding specific attribution requirements, to ensure that all references of Registry as the source of Data are accurate and consistent in any publications].
    * 比較結果：一致
    * 判断理由：UKBBは出版物のタイトルや要約に"UK Biobank"という用語を含めることを要求しており、NIHは出版物でのデータソースの正確な帰属を確保するための特定の帰属要件を追加することを検討するとしています。
* **5.15 UK Biobank requires that any and all publications of Findings using UK Biobank data include the following credit, which should be incorporated within the "Acknowledgements" of such publication: "This research has been conducted using the UK Biobank Resource under application number [ ]."**
    * 対応するEGAの条文：7. The User Institution agrees to follow the Fort Lauderdale Guidelines... This includes but is not limited to recognising the contribution of the Data Producers and including a proper acknowledgement in all reports or publications resulting from the use of these Data.
    * 比較結果：一致
    * 判断理由：UKBBとEGAは、出版物にデータ提供者への適切な謝辞を含めることを要求しています。
    * 対応するNIHの条文：9.b. [Registry may consider adding specific attribution requirements, to ensure that all references of Registry as the source of Data are accurate and consistent in any publications].
    * 比較結果：一致
    * 判断理由：UKBBは特定の謝辞を含めることを要求しており、NIHは出版物でのデータソースの正確な帰属を確保するための特定の帰属要件を追加することを検討するとしています。
* **5.16 This acknowledgement to UK Biobank should, when possible, be linked to reference search tools (such as PubMed and MEDLINE and/or DOI reference).**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **6. Charges**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **6.1 The Applicant agrees to pay the Access Charges as set out in the payment section of the Applicant's Application to UK Biobank via bank transfer or Sage Pay, and in British pounds sterling (GBP). The Access Charges are stated to be exclusive of VAT. The Applicant shall pay any applicable VAT in addition to the Access Charges.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文：2. Cost Jor No Cost
    * 比較結果：一致
    * 判断理由：UKBBはアクセス料の支払いについて規定しており、NIHはデータ提供に費用がかかるかどうか、および研究者が費用を負担することを規定しています。
* **6.2 When paying the Access Charges, the Applicant shall quote the invoice number and/or Application Reference Number as the payment reference, and also send a remittance note to creditcontrol@ukbiobank.ac.uk.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **6.3 The rights granted to the Applicant by UK Biobank under this MTA are conditional on the Access Charges (and applicable VAT) being paid and so, for the avoidance of doubt, no Materials shall be provided to the Applicant until or unless the Access Charges (and applicable VAT) are received in full.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません
* **6.4 If payment of the Access Charges (and applicable VAT) has not been made within ninety (90) days of receipt of this MTA by the Applicant, the Applicant shall be required to re-apply for access to the UK Biobank resource and Materials.**
    * 対応するEGAの条文はありません
    * 対応するNIHの条文はありません